Formation Biologics Inc., a company more commonly called Forbius that's developing biologics for fibrosis and cancer, has dosed the first patient in a phase IIa study designed to evaluate its EGFR-targeting antibody-drug conjugate, AVID-100, in patients with EGFR-overexpressing squamous cell carcinoma of the head and neck (SCCHN).